Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC.
Radiat Oncol
; 17(1): 124, 2022 Jul 16.
Article
in En
| MEDLINE
| ID: mdl-35842660
ABSTRACT
BACKGROUND:
tumor recurrence after NSCLC surgical resection is the most common cause of treatment failure that sharply reduces the patient's life expectancy. The optimal treatment strategy for loco-regional recurrences developing after surgical resection in patients with non-small-cell lung cancer (NSCLC) is not established yet. This report aims to describe the pattern of relapse, PFS, and OS in patients treated with radio-chemotherapy and durvalumab for loco-regional relapse after surgery.METHODS:
We conducted a multicenter, retrospective study including subjects who underwent surgical resection for NSCLC and were treated with Pacific protocol after loco-regional relapse.RESULTS:
Twenty-four patients met the inclusion criteria. At the time of diagnosis mean age was 65 years (range 47-78), the majority being male (58.3%). The 12-month progression-free survival rate was 68.7%, the 18-month progression-free survival rate was 45.8%, and the 24-month progression-free survival rate was 34.3%. There were three deaths the 12-month survival rate was 91%, and the 18-month survival rate was 82.8%.CONCLUSIONS:
In this article, we propose a treatment strategy that might prolong post recurrence survival in patients with good performance status experiencing loco-regional relapse after surgery.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Lung Neoplasms
Type of study:
Guideline
/
Observational_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Radiat Oncol
Journal subject:
NEOPLASIAS
/
RADIOTERAPIA
Year:
2022
Document type:
Article
Affiliation country:
Italy